---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-064374"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:17:33.507997+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Candel reports positive final Phase 2a data for CAN-2409 in NSCLC; mOS 24.5 months, long survival tail

## Summary
- mOS of 24.5 months in evaluable patients (cohort 1+2, n=46) with advanced NSCLC inadequately responding to ICI.
- In patients with progressive disease at baseline (cohort 2, n=41), mOS was 21.5 months, vs. 9.8–11.8 months for docetaxel.
- 37% (15/41) of progressive disease patients alive >24 months; long tail of survival observed.
- In non-squamous NSCLC (n=33), mOS was 25.4 months; ITT analysis showed 16.7 months vs. 9.9–12.3 months for SOC.
- Systemic anti-tumor response (abscopal effect) seen in 69% of patients with multiple lesions; safety profile favorable.

## SEC filing metadata
- accession: 0001193125-25-064374
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312525064374/0001193125-25-064374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312525064374/d917988d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-064374
- JSON: https://secwatch.observer/filing/0001193125-25-064374.json
- Plain text: https://secwatch.observer/filing/0001193125-25-064374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.